STOCK TITAN
  1. Home
  2. Sec-filings
  3. BLTE
  4. [Form 4] BELITE BIO, INC Insider Trading Activity

Bioptima Ltd. tied to Belite Bio (BLTE) CMO sells 10,000 ADSs in open market

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Belite Bio Chief Medical Officer-linked entity sells ADSs. Bioptima Ltd., an entity associated with Chief Medical Officer Hendrik Peter Scholl, reported open-market sales totaling 10,000 American depositary shares of Belite Bio on June 18, 2026. The trades were executed in multiple blocks at prices ranging from about $143.90 to $147.11 per ADS, with some prices disclosed as weighted averages across narrower intraday ranges. Following these transactions, Bioptima Ltd. indirectly holds 24,904 American depositary shares of Belite Bio.

Positive

  • None.

Negative

  • None.
Insider Scholl Hendrik Peter
Role Chief Medical Officer
Sold 10,000 shs ($1.45M)
Type Security Shares Price Value
Sale American depositary share 96 $143.90 $14K
Sale American depositary share 3,748 $144.6617 $542K
Sale American depositary share 4,861 $145.4348 $707K
Sale American depositary share 1,199 $146.2449 $175K
Sale American depositary share 96 $147.11 $14K
Holdings After Transaction: American depositary share — 24,904 shares (Indirect, By Bioptima Ltd.)
Footnotes (1)
  1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer. Represents the weighted average price of shares sold at prices that ranged from $144.07 to $144.995. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $145 to $145.94. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $146.005 to $146.755. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
Total ADSs sold 10,000 American depositary shares Open-market sales on June 18, 2026
First block sale price $147.1100 per ADS 96 ADSs sold on June 18, 2026
Second block sale price $146.2449 per ADS 1,199 ADSs sold on June 18, 2026
Largest block sale price $145.4348 per ADS 4,861 ADSs sold on June 18, 2026
Additional block sale price $144.6617 per ADS 3,748 ADSs sold on June 18, 2026
Lowest reported sale price $143.9000 per ADS 96 ADSs sold on June 18, 2026
Indirect holdings after sales 24,904 American depositary shares Bioptima Ltd. post-transaction position
American depositary share financial
"Each American depositary share represents one ordinary share, par value US$0.0001 per share"
An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.
open-market sale financial
"transaction_action: open-market sale and transaction_code_description: Sale in open market"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
indirect financial
"direct_or_indirect: I and ownership_type: indirect for Bioptima Ltd."
weighted average price financial
"Represents the weighted average price of shares sold at prices that ranged from"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Scholl Hendrik Peter
(Last)(First)(Middle)
GOTTHARDSTRASSE 26
(Street)
ZUGSWITZERLAND6300
(City)(State)(Zip)
SWITZERLAND
(Country)		2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
American depositary share(1)06/18/2026S96D$143.924,904IBy Bioptima Ltd.
American depositary share(1)06/18/2026S3,748D$144.6617(2)21,156IBy Bioptima Ltd.
American depositary share(1)06/18/2026S4,861D$145.4348(3)16,295IBy Bioptima Ltd.
American depositary share(1)06/18/2026S1,199D$146.2449(4)15,096IBy Bioptima Ltd.
American depositary share(1)06/18/2026S96D$147.1115,000IBy Bioptima Ltd.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
2. Represents the weighted average price of shares sold at prices that ranged from $144.07 to $144.995. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
3. Represents the weighted average price of shares sold at prices that ranged from $145 to $145.94. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
4. Represents the weighted average price of shares sold at prices that ranged from $146.005 to $146.755. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
/s/ Hendrik Peter Scholl06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Belite Bio (BLTE) report for Hendrik Peter Scholl?

Belite Bio reported that Bioptima Ltd., linked to Chief Medical Officer Hendrik Peter Scholl, sold 10,000 American depositary shares. The sales were open-market transactions executed in multiple blocks on June 18, 2026 at various prices around $144–$147 per ADS.

How many Belite Bio (BLTE) shares were sold in the latest Form 4 filing?

The Form 4 shows total open-market sales of 10,000 American depositary shares. These were split across several trades, including blocks of 4,861, 3,748, 1,199 and smaller 96-share lots, all executed on June 18, 2026 at different prices.

At what prices were the Belite Bio (BLTE) insider sales executed?

The reported trades occurred at prices from $143.90 to $147.11 per ADS. Several entries disclose weighted average prices, with underlying individual sale prices falling within narrower ranges between about $144.07 and $146.755, all on June 18, 2026.

Who actually holds the Belite Bio (BLTE) shares involved in the Form 4 transactions?

The shares are held indirectly through Bioptima Ltd. The Form 4 lists ownership as indirect with the nature of ownership described as “By Bioptima Ltd.” for all reported American depositary share sales on June 18, 2026.

What do the weighted average price footnotes mean in the Belite Bio (BLTE) Form 4?

Some reported prices are weighted averages for multiple trades within a range. The Form 4 notes that shares were sold in several executions between specified price bands, and the reporting person will provide exact per-trade details upon request to regulators or security holders.